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Background: An association between tumor-specific HMG-CoA reductase (HMGCR) expression and good prognosis
has previously been demonstrated in breast and ovarian cancer. In this study, the expression, clinicopathological
correlates and prognostic value of HMGCR expression in colorectal cancer was examined.
Findings: Immunohistochemical expression of HMGCR was assessed in tissue microarrays with primary tumours
from 557 incident cases of colorectal cancer in the Malmö Diet and Cancer Study. Pearson’s Chi Square test
was applied to explore the associations between HMGCR expression and clinicopathological factors and other
investigative biomarkers. Kaplan Meier analysis and Cox proportional hazards modeling were used to assess the
relationship between HMGCR expression and cancer-specific survival (CSS) according to negative vs positive
HMGCR expression.
A total number of 535 (96.0%) tumours were suitable for analysis, of which 61 (11.4%) were HMGCR negative.
Positive cytoplasmic HMGCR expression was associated with distant metastasis-free disease at diagnosis (p = 0.002),
lack of vascular invasion (p = 0.043), microsatellite-instability (p = 0.033), expression of cyclin D1 (p = <0.001) and p21
(p = <0.001). Positive HMGCR expression was significantly associated with a prolonged CSS in unadjusted Cox
regression analysis in the entire cohort (HR = 1.79; 95% CI 1.20-2.66) and in Stage III-IV disease (HR = 1.71; 95%
CI 1.09-2.68), but not after adjustment for established clinicopathological parameters.
Conclusions: Findings from this prospective cohort study demonstrate that HMGCR is differentially expressed in
colorectal cancer and that positive expression is associated with favourable tumour characteristics and a prolonged
survival in unadjusted analysis. The utility of HMGCR as a predictor of response to neoadjuvant or adjuvant statin
treatment in colorectal cancer merits further study.
Virtual slides: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
2115647072103464.
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Background
Colorectal cancer (CRC) is the third most common form
of cancer in the world, with an estimated annual global
incidence of more than 1.2 million new cases and
around 600 000 deaths from the disease [1]. Although
many efforts have been made to find molecular markers
to identify high-risk disease and to select patients for ad-
juvant treatment, none have yet been implemented into
routine clinical practice.
It has recently been demonstrated that elevated expres-
sion of the enzyme 3-hydroxy-3-methylglutharyl-coenzyme
A reductase (HMGCR) correlates with favourable prog-
nosis in breast and ovarian cancer [2,3], and with an
improved response to tamoxifen [4] and pre-surgical
statin treatment [5] in breast cancer. Several epidemio-
logical studies have shown a link between use of statins,
inhibitors of HMGCR, and a significantly reduced CRC
incidence [6-8], and statins have also been demon-
strated to exert anti-neoplastic properties in CRC cells
in vitro [9,10].
To the best of our knowledge, the expression and
prognostic significance of HMGCR in CRC has not yet
been reported. The aim of this study was therefore to
analyse tumour-specific expression of HMGCR by im-
munohistochemistry in tissue microarrays (TMAs) with
primary tumour specimens from incident CRC cases di-
agnosed within a large, prospective cohort study, and to
explore its relationship with established clinicopathologi-
cal and tumor biological parameters, and survival.
Methods
Until 31 Dec 2008, 626 incident cases of CRC had been
registered in the Malmö Diet and Cancer Study (MDCS)
[11-13]. Cases were identified from the Swedish Cancer
Registry up until 31 Dec 2007, and from The Southern
Swedish Regional Tumour Registry for the period of 1
Jan - 31 Dec 2008. Information on vital status and cause
of death was obtained from the Swedish Cause of Death
Registry up until 31 Dec 2009. Follow-up started at date
of diagnosis and ended at the date of death, emigration
or end of follow-up, whichever came first. All tumours
with available slides or paraffin blocks were histopatho-
logically re-evaluated on haematoxylin and eosin stained
slides. Histopathological, clinical and treatment data were
obtained from the clinical and/or pathology records. TNM
staging was performed according to the American Joint
Committee on Cancer (AJCC) [14]. Patient and tumour
characteristics of the cohort have been described in detail
previously [15-19]. Ethical permission was obtained from
the Ethics Committee at Lund University (Ref. nr 51/90
and 530/2008).
TMAs were constructed as previously described using
duplicate 1.00 mm cores [16].For immunohistochemical analysis of HMGCR, 4 μm
TMA-sections were automatically pre-treated using the
PT-link system (DAKO, Glostrup, Denmark) and then
stained in an Autostainer Plus (DAKO) with a polyclonal
anti-HMGCR antibody HPA008338, Atlas Antibodies
AB, Stockholm, Sweden diluted 1:150. This antibody
has been validated (www.proteinatlas.org) and used in
a recent window-of-opportunity statin trial in breast
cancer [5].
HMGCR was expressed in the cytoplasm of the
tumour cells, without distinct membranous staining
as previously shown in e.g. breast cancer [2]. In line
with previous studies, HMGCR was generally expressed
in >50 percent of tumour cells in all positive cases
[2,3,20]. Therefore, only the cytoplasmic staining intensity
was taken into account, and denoted as 0 = >1% of cells
being negative, 1 = weak expression in any fraction >1%,
and 2 =moderate/strong expression in any fraction >1%.
The staining was evaluated by three independent ob-
servers, who were blinded to clinical and outcome data
(EB, PN and KJ). Scoring differences were discussed in
order to reach consensus.
Immunohistochemical staining and evaluation of cyc-
lin D1, p21, p27, p53, and beta-catenin expression has
been described previously [15,17]. Immunohistochemical
staining for microsatellite instability (MSI) screening sta-
tus was performed as previously described, whereby tu-
mours lacking expression of any of the DNA mismatch
repair proteins MLH1, PMS2, MSH2 or MSH6 were de-
noted as having a positive MSI screening status, and tu-
mours expressing all MMR proteins as being microsatellite
stable (MSS) [18]. Analysis of KRAS and BRAF mutational
status was performed by pyrosequencing as previously
described [21,22]. Pearson’s Chi Square test was used to ex-
plore the associations of HMGCR expression with clinico-
pathological and investigative parameters. Kaplan-Meier
analysis and log rank test were used to illustrate differences
in cancer specific survival (CSS) according to negative vs
positive HMGCR expression. Cox regression proportional
hazards models were used for estimation of hazard ratios
(HRs) for death from CRC and overall death in both uni-
and multivariable analysis, the latter adjusted for age, sex,
tumour (T)-stage, lymph node metastasis (N-stage), distant
metastasis (M-stage), differentiation grade, vascular inva-
sion and MSI status. A backward conditional selection
method was used for variable selection by the model. All
tests were two-sided. A p-value of 0.05 was considered sig-
nificant. All statistical analyses were performed using IBM
SPSS Statistics version 20.0.
Results
HMGCR expression could be evaluated in 535 (96.0%)
cases, of which 61 (11.4%) were negative, 206 (38.5%) dis-
played weak and 268 (50.1%) displayed strong expression.
Table 1 Significant associations of HMG-CoA reductase
expression with clinicopathological characteristics and
investigative factors
HMG-CoA reductase expression
Factor Negative Positive P-value
N(%) 61 (11.4) 474 (88.6)
M stage
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Figure 1. Normal colonic mucosa displays moderate-strong
HMGCR expression (www.proteinatlas.org).
As shown in Table 1, there were significant associations
between HMGCR expression and distant metastasis-free
disease (p = 0.002), lack of vascular invasion (p = 0.043)
and positive MSI screening status (p = 0.033). Moreover,Figure 1 HMG-CoA reductase expression in colorectal cancer.
Sample immuohistochemical images (10X) of primary colorectal
cancer with (A) negative; (B) weak and (C) strong HMG-CoA
reductase expression.
0 41(68.3) 395 (84.4) 0.002
1 19 (31.7) 73 (15.6)
Missing 1 6
Vascular invasion
No 11 (32.4) 142 (50.7) 0.043
Yes 23 (67.6) 138 (49.3)
Missing 17 194
Microsatellite instability
MSS 52(94.5) 371 (83.6) 0.033
MSI 3 (5.5) 73 (16.4)
Missing 6 30
Cyclin D1 expression
Negative 22 (37.3) 80 (17.7) <0.001
Positive 37 (62.7) 371 (82.3)
Missing 2 23
p21 expression
Negative 20 (33.9) 53 (11.8) <0.001
Positive 39 (66.1) 396 (88.2)
missing 2 25
The categories marked as missing were not included in the analysis.HMGCR expression was significantly associated with ex-
pression of cyclin D1 (p < 0.001) and p21 (p < 0.001). There
were no significant associations between HMGCR expres-
sion and age, sex, T-stage, N-stage, differentiation grade,
mucinous histology, beta-catenin grades, p53 status, KRAS
or BRAF mutation (data not shown).
Kaplan-Meier analysis and log rank test revealed a sig-
nificant association between positive HMGCR expres-
sion and a prolonged CSS in the full cohort and in Stage
III-IV (metastatic) disease, but not in Stage I-II (non-
metastatic) disease (Figure 2). Notably, survival rates were
similar for tumours with weak and moderate/strong ex-
pression (Figure 2).
Unadjusted Cox regression analysis confirmed the sig-
nificant correlation between positive HMGCR expression
and an improved CSS in the entire cohort (HR = 1.79; 95%
CI 1.20-2.66) and in stage III-IV disease (HR = 1.71 (1.09-
2.68) (Table 2). However, these associations did not remain
significant in multivariable Cox regression analysis, ad-
justed for age, sex, T-stage, N-stage, M-stage, differenti-
ation grade, vascular invasion and MSI status (Table 2).
Similar associations were found using overall survival as
Figure 2 Kaplan-Meier estimates of the prognostic impact of HMG-CoA reductase expression. Kaplan Meier analysis and log rank test of
colorectal cancer specific survival according to negative, weak and strong HMGCR expression in (A) all patients, (B) patients with stage I-II disease
and (C) patients with stage III-IV disease.
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HMGCR did not differ by sex or tumour location
(data not shown). There was no significant association be-
tween HMGCR expression and response to adjuvant treat-
ment in curatively treated patients with stage III-IV disease
(data not shown).
Discussion
The results from this comparatively large cohort study
demonstrate that HMGCR expression in CRC is associ-
ated with clinically less advanced tumours and a more
favourable prognosis. These findings are in line with pre-
vious studies on e.g. breast and ovarian cancer [2,3].
The correlation between HMGCR expression and a
prolonged CSS did however not remain significant in ad-
justed analysis, and the lack of independent prognostic
information for HMGCR expression may be explained
by its significant association with established prognostic
factors, in particular M-stage and vascular invasion. As
the results in this study are entirely based on analysis of
primary tumours, it would also be of interest to compare
HMGCR expression in primary and metastatic lesions in
future studies [23,24]. Moreover, as data on recurrentTable 2 Cox proportional hazards analysis of colorectal cancer s
Full cohort
HR (95%CI) n (events) HR (95
Unadjusted
HMGCR pos 1.00 474 (153) 1,0
HMGCR neg 1.79 (1-20-2.66) 61 (29) 1.56 (0.6
Adjusted
HMGCR pos 1.00 406 (126) 1.0
HMGCR neg 0.85 (0.51-1.41) 45 (19) 1.23 (0.4
Multivariable analysis included adjustment for age (continuous), T-stage (1-2, 3, 4), s
vascular invasion (no, yes, unknown) and MSI screening status.disease was not available for the patients in this cohort,
future studies should also consider the association of
HMGCR expression with to time to recurrence, prefera-
bly in cohorts where this information has been recorded
prospectively.
The finding of an association between HMGCR ex-
pression and positive MSI screening status is of potential
interest, as MSI tumours may be less responsive to adju-
vant treatment with 5-fluorouracil-based chemotherapy
[25-27]. Speculatively, CRC patients with MSI/HMCGR
expressing tumours may instead benefit from adjuvant
statin treatment, in particular as HMGCR expression
has been demonstrated to predict an improved response
to pre-surgical statin treatment in breast cancer [5]. Not-
ably, in this cohort, positive MSI status has been demon-
strated to be associated with a significantly improved
prognosis in patients with stage III-IV disease, but not to
be predictive of response to adjuvant chemotherapy [15].
Future studies should also address whether HMGCR ex-
pression in CRC is affected by different neoadjuvant
treatment regimens [24,28].
Unfortunately, it was not possible to examine associa-
tions of HMGCR expression with statin use in this cohort,pecific survival according to HMG-CoA reductase expression
Stage I-II disease Stage I-II disease
%CI) n (events) HR (95%CI) n (events)
Unadjusted Unadjusted
0 243 (33) 1,00 208 (116)
1-4.01) 25 (5) 1.71 (1.09-2.68) 31 (23)
Adjusted Adjusted
0 227 (30) 1.00 179 (96)
1-3.70) 23 (4) 0.82 (0.46-1.46) 22 (15)
ex, N-stage (0,1,2), M-stage, differentiation grade (high-intermediate vs. low),
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reported at baseline was too small [2]. However, a previous
study demonstrated associations of high tumour-specific
HMGCR expression in post-menopausal breast cancer
with use of hormone replacement therapy and obesity [2].
These findings suggest that the influence of lifestyle factors
and anthropometric measures on HMGCR expression in
CRC also merits further study.
Statin-mediated blockade of the mevalonate pathway
triggers a marked increase of inactive HMGCR in cul-
tured cells [29] and statin treatment has also been dem-
onstrated to induce cell cycle arrest and up-regulation of
p21 and p27 in colorectal cancer in vitro [10]. In this
context, the significant associations of HMGCR expres-
sion with expression of p21 and cyclin D1found here
also indicate a potential cell-cycle regulatory role for
HMGCR in colorectal cancer in vivo. Of note, high cyc-
lin D1 expression has previously been found to correlate
with good prognosis in this cohort, in particular in male
CRC [17].
Conclusions
This study provides a first report of tumour-specific
HMGCR in colorectal cancer, and its association with
favourable clinicopathological characteristics and an im-
proved prognosis. The utility of HMGCR expression as a
predictor of response to different neoadjuvant or adju-
vant treatment regimens in colorectal cancer should be
investigated in future studies.
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